secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2026-08-27T20:15:47+00:00
Accession:  0001140361-26-034698
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences acquired by argenx for $77.00/share, ~$2.2B; delisting planned
--------------------------------------------------------------------------------

- Tender offer accepted 19,894,879 shares (~87.13% of outstanding) at $77.00/share cash.
- Merger completed Aug 27, 2026; Forte is now a wholly owned subsidiary of argenx BV.
- Total consideration ~$2.2B funded from argenx cash; covers options, RSUs, warrants.
- All prior directors/officers replaced; new board includes Arjen Lemmen, Karl Gubitz, Malini Moorthy.
- Company requested Nasdaq delisting and will file Form 15 to suspend SEC reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000114036126034698/0001140361-26-034698-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000114036126034698/ef20081182_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-034698

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer